Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Neurotherapeutics
Erschienen in: Neurotherapeutics 4/2018

01.10.2018 | Review

Skeletal Muscle Channelopathies

verfasst von: Lauren Phillips, Jaya R. Trivedi

Erschienen in: Neurotherapeutics | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Skeletal muscle channelopathies are rare heterogeneous diseases with marked genotypic and phenotypic variability. These disorders cause lifetime disability and impact quality of life. Despite advances in understanding of the molecular pathology of these disorders, the diverse phenotypic manifestations remain a challenge in diagnosis, therapeutic, genetic counseling, and research planning. Electrodiagnostic testing is useful in directing the diagnosis, but has several limitations: patient discomfort, time consuming, and significant overlap of findings in muscle channelopathies. Although genetic testing is the gold standard in making a definitive diagnosis, a mutation might not be identified in many patients with a well-supported clinical diagnosis of periodic paralysis. In the recent past, there have been landmark clinical trials in non-dystrophic myotonia and periodic paralysis which are encouraging as they demonstrate the ability of robust clinical research consortia to conduct well-controlled trials of rare diseases.
Literatur
1.
Raja Rayan DL, Hanna MG. Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis. Curr Opin Neurol. 2010;23(5):466–76.CrossRefPubMed
2.
Statland JM, Barohn RJ. Muscle channelopathies: the nondystrophic myotonias and periodic paralyses. Continuum (Minneap Minn). 2013;19(6 Muscle Disease):1598–614.PubMedPubMedCentral
3.
Paninka RM, Carlos-Lima E, Lindsey SC, Kunii IS, Dias-da-Silva MR, Arcisio-Miranda M. Down-regulation of Kir2.6 channel by c-termini mutation D252N and its association with the susceptibility to Thyrotoxic Periodic Paralysis. Neuroscience. 2017;346:197–202.CrossRefPubMed
4.
Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci. 2006;29:387–415.CrossRefPubMed
5.
Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord. 1991;1(1):19–29.CrossRefPubMed
6.
Fialho D, Schorge S, Pucovska U, Davies NP, Labrum R, Haworth A, et al. Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. Brain. 2007;130(Pt 12):3265–74.CrossRefPubMed
7.
Hoffman EP, Wang J. Duchenne-Becker muscular dystrophy and the nondystrophic myotonias. Paradigms for loss of function and change of function of gene products. Arch Neurol. 1993;50(11):1227–37.CrossRefPubMed
8.
Lehmann-Horn F, Rudel R. Channelopathies: the nondystrophic myotonias and periodic paralyses. Semin Pediatr Neurol. 1996;3(2):122–39.CrossRefPubMed
9.
Pinessi L, Bergamini L, Cantello R, Di Tizio C. Myotonia congenita and myotonic dystrophy: descriptive epidemiological investigation in Turin, Italy (1955-1979). Ital J Neurol Sci. 1982;3(3):207–10.CrossRefPubMed
10.
Ptacek LJ, George AL, Jr., Griggs RC, Tawil R, Kallen RG, Barchi RL, et al. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell. 1991;67(5):1021–7.CrossRefPubMed
11.
Sun C, Tranebjaerg L, Torbergsen T, Holmgren G, Van Ghelue M. Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia. Eur J Hum Genet. 2001;9(12):903–9.CrossRefPubMed
12.
Lion-Francois L, Mignot C, Vicart S, Manel V, Sternberg D, Landrieu P, et al. Severe neonatal episodic laryngospasm due to de novo SCN4A mutations: a new treatable disorder. Neurology. 2010;75(7):641–5.CrossRefPubMed
13.
Orrell RW, Jurkat-Rott K, Lehmann-Horn F, Lane RJ. Familial cramp due to potassium-aggravated myotonia. J Neurol Neurosurg Psychiatry. 1998;65(4):569–72.CrossRefPubMedPubMedCentral
14.
Lacomis D, Gonzales JT, Giuliani MJ. Fluctuating clinical myotonia and weakness from Thomsen’s disease occurring only during pregnancies. Clin Neurol Neurosurg. 1999;101(2):133–6.CrossRefPubMed
15.
Fialho D, Kullmann DM, Hanna MG, Schorge S. Non-genomic effects of sex hormones on CLC-1 may contribute to gender differences in myotonia congenita. Neuromuscul Disord. 2008;18(11):869–72.CrossRefPubMed
16.
Basu A, Nishanth P, Ifaturoti O. Pregnancy in women with myotonia congenita. Int J Gynaecol Obstet. 2009;106(1):62–3.CrossRefPubMed
17.
Sun C, Van Ghelue M, Tranebjaerg L, Thyssen F, Nilssen O, Torbergsen T. Myotonia congenita and myotonic dystrophy in the same family: coexistence of a CLCN1 mutation and expansion in the CNBP (ZNF9) gene. Clin Genet. 2011;80(6):574–80.CrossRefPubMed
18.
Suominen T, Schoser B, Raheem O, Auvinen S, Walter M, Krahe R, et al. High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany. J Neurol. 2008;255(11):1731–6.CrossRefPubMedPubMedCentral
19.
Bugiardini E, Rivolta I, Binda A, Soriano Caminero A, Cirillo F, Cinti A, et al. SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype. Neuromuscul Disord. 2015;25(4):301–7.CrossRefPubMed
20.
21.
Colding-Jorgensen E. Phenotypic variability in myotonia congenita. Muscle Nerve. 2005;32(1):19–34.CrossRefPubMed
22.
Streib EW. Paramyotonia congenita: successful treatment with tocainide. Clinical and electrophysiologic findings in seven patients. Muscle Nerve. 1987;10(2):155–62.CrossRefPubMed
23.
Becker PE, Knussmann R, Kuhn E. Myotonia congenita and syndromes associated with myotonia : clinical-genetic studies of the nondystrophic myotonias. Stuttgart: Thieme; 1977. x, 181 p. p.
24.
Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, et al. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain. 2013;136(Pt 7):2189–200.CrossRefPubMedPubMedCentral
25.
Trip J, Drost G, Ginjaar HB, Nieman FH, van der Kooi AJ, de Visser M, et al. Redefining the clinical phenotypes of non-dystrophic myotonic syndromes. J Neurol Neurosurg Psychiatry. 2009;80(6):647–52.CrossRefPubMed
26.
Ptacek LJ, Trimmer JS, Agnew WS, Roberts JW, Petajan JH, Leppert M. Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus. Am J Hum Genet. 1991;49(4):851–4.PubMedPubMedCentral
27.
Ptacek LJ, Tyler F, Trimmer JS, Agnew WS, Leppert M. Analysis in a large hyperkalemic periodic paralysis pedigree supports tight linkage to a sodium channel locus. Am J Hum Genet. 1991;49(2):378–82.PubMedPubMedCentral
28.
Fontaine B. Periodic paralysis, myotonia congenita and sarcolemmal ion channels: a success of the candidate gene approach. Neuromuscul Disord. 1993;3(2):101–7.CrossRefPubMed
29.
Ptacek LJ, Johnson KJ, Griggs RC. Genetics and physiology of the myotonic muscle disorders. N Engl J Med. 1993;328(7):482–9.CrossRefPubMed
30.
Matthews E, Tan SV, Fialho D, Sweeney MG, Sud R, Haworth A, et al. What causes paramyotonia in the United Kingdom? Common and new SCN4A mutations revealed. Neurology. 2008;70(1):50–3.CrossRefPubMed
31.
Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain. 2010;133(Pt 1):9–22.CrossRefPubMed
32.
Ptacek LJ, George AL, Jr., Barchi RL, Griggs RC, Riggs JE, Robertson M, et al. Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita. Neuron. 1992;8(5):891–7.CrossRefPubMed
33.
Ricker K, Moxley RT, III, Heine R, Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol. 1994;51(11):1095–102.CrossRefPubMed
34.
Trudell RG, Kaiser KK, Griggs RC. Acetazolamide-responsive myotonia congenita. Neurology. 1987;37(3):488–91.CrossRefPubMed
35.
Singh RR, Tan SV, Hanna MG, Robb SA, Clarke A, Jungbluth H. Mutations in SCN4A: a rare but treatable cause of recurrent life-threatening laryngospasm. Pediatrics. 2014;134(5):e1447–50.CrossRefPubMed
36.
Matthews E, Silwal A, Sud R, Hanna MG, Manzur AY, Muntoni F, et al. Skeletal Muscle Channelopathies: Rare Disorders with Common Pediatric Symptoms. J Pediatr. 2017;188:181–5 e6.CrossRefPubMed
37.
38.
39.
Hanisch F, Kraya T, Kornhuber M, Zierz S. Diagnostic impact of myotonic discharges in myofibrillar myopathies. Muscle Nerve. 2013;47(6):845–8.CrossRefPubMed
40.
Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. 2004;56(5):650–61.CrossRefPubMed
41.
Fournier E, Viala K, Gervais H, Sternberg D, Arzel-Hezode M, Laforet P, et al. Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol. 2006;60(3):356–65.CrossRefPubMed
42.
McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve. 1986;9(8):704–10.CrossRefPubMed
43.
Tan SV, Matthews E, Barber M, Burge JA, Rajakulendran S, Fialho D, et al. Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies. Ann Neurol. 2011;69(2):328–40.CrossRefPubMedPubMedCentral
44.
Morrow JM, Matthews E, Raja Rayan DL, Fischmann A, Sinclair CD, Reilly MM, et al. Muscle MRI reveals distinct abnormalities in genetically proven non-dystrophic myotonias. Neuromuscul Disord. 2013;23(8):637–46.CrossRefPubMedPubMedCentral
45.
Wu FF, Ryan A, Devaney J, Warnstedt M, Korade-Mirnics Z, Poser B, et al. Novel CLCN1 mutations with unique clinical and electrophysiological consequences. Brain. 2002;125(Pt 11):2392–407.CrossRefPubMed
46.
Saviane C, Conti F, Pusch M. The muscle chloride channel ClC-1 has a double-barreled appearance that is differentially affected in dominant and recessive myotonia. J Gen Physiol. 1999;113(3):457–68.CrossRefPubMedPubMedCentral
47.
Bryant SH, Morales-Aguilera A. Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids. J Physiol. 1971;219(2):367–83.CrossRefPubMedPubMedCentral
48.
49.
Pusch M, Steinmeyer K, Koch MC, Jentsch TJ. Mutations in dominant human myotonia congenita drastically alter the voltage dependence of the CIC-1 chloride channel. Neuron. 1995;15(6):1455–63.CrossRefPubMed
50.
Koch MC, Steinmeyer K, Lorenz C, Ricker K, Wolf F, Otto M, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992;257(5071):797–800.CrossRefPubMed
51.
George AL, Jr., Crackower MA, Abdalla JA, Hudson AJ, Ebers GC. Molecular basis of Thomsen’s disease (autosomal dominant myotonia congenita). Nat Genet. 1993;3(4):305–10.CrossRefPubMed
52.
George AL, Jr., Sloan-Brown K, Fenichel GM, Mitchell GA, Spiegel R, Pascuzzi RM. Nonsense and missense mutations of the muscle chloride channel gene in patients with myotonia congenita. Hum Mol Genet. 1994;3(11):2071–2.PubMed
53.
Meyer-Kleine C, Steinmeyer K, Ricker K, Jentsch TJ, Koch MC. Spectrum of mutations in the major human skeletal muscle chloride channel gene (CLCN1) leading to myotonia. Am J Hum Genet. 1995;57(6):1325–34.PubMedPubMedCentral
54.
Zhang J, George AL, Jr., Griggs RC, Fouad GT, Roberts J, Kwiecinski H, et al. Mutations in the human skeletal muscle chloride channel gene (CLCN1) associated with dominant and recessive myotonia congenita. Neurology. 1996;47(4):993–8.CrossRefPubMed
55.
Papponen H, Toppinen T, Baumann P, Myllyla V, Leisti J, Kuivaniemi H, et al. Founder mutations and the high prevalence of myotonia congenita in northern Finland. Neurology. 1999;53(2):297–302.CrossRefPubMed
56.
Lehmann-Horn F, Rudel R, Dengler R, Lorkovic H, Haass A, Ricker K. Membrane defects in paramyotonia congenita with and without myotonia in a warm environment. Muscle Nerve. 1981;4(5):396–406.CrossRefPubMed
57.
Lehmann-Horn F, Rudel R, Ricker K, Lorkovic H, Dengler R, Hopf HC. Two cases of adynamia episodica hereditaria: in vitro investigation of muscle cell membrane and contraction parameters. Muscle Nerve. 1983;6(2):113–21.CrossRefPubMed
58.
Fontaine B, Khurana TS, Hoffman EP, Bruns GA, Haines JL, Trofatter JA, et al. Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene. Science. 1990;250(4983):1000–2.CrossRefPubMed
59.
Ebers GC, George AL, Barchi RL, Ting-Passador SS, Kallen RG, Lathrop GM, et al. Paramyotonia congenita and hyperkalemic periodic paralysis are linked to the adult muscle sodium channel gene. Ann Neurol. 1991;30(6):810–6.CrossRefPubMed
60.
61.
Rose MR, Sadjadi R, Weinman J, Akhtar T, Pandya S, Kissel JT, et al. Role of disease severity, illness perceptions, and mood on quality of life in muscle disease. Muscle Nerve. 2012;46(3):351–9.CrossRefPubMed
62.
Sansone VA, Ricci C, Montanari M, Apolone G, Rose M, Meola G. Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol. 2012;19(11):1470–6.CrossRefPubMedPubMedCentral
63.
64.
Statland J, Phillips L, Trivedi JR. Muscle channelopathies. Neurol Clin. 2014;32(3):801–15, x.CrossRefPubMed
65.
Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012;308(13):1357–65.CrossRefPubMedPubMedCentral
66.
Arnold WD, Kline D, Sanderson A, Hawash AA, Bartlett A, Novak KR, et al. Open-label trial of ranolazine for the treatment of myotonia congenita. Neurology. 2017;89(7):710–3.CrossRefPubMedPubMedCentral
67.
Dunø M, Colding-Jørgensen E. Myotonia Congenita. In: Pagon RA AM, Bird TD, Dolan CR, Fong CT, Stephens K, editors, editor. GeneReviews [Internet]. University of Washington, Seattle2005 [updated 2011 Apr 12]. .
68.
Aichele R, Paik H, Heller AH. Efficacy of phenytoin, procainamide, and tocainide in murine genetic myotonia. Exp Neurol. 1985;87(2):377–81.CrossRefPubMed
69.
Desaphy JF, Modoni A, Lomonaco M, Camerino DC. Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy. Eur J Clin Pharmacol. 2013;69(4):1037–9.CrossRefPubMed
70.
Berardinelli A, Gorni K, Orcesi S. Response to carbamazepine of recessive-type myotonia congenita. Muscle Nerve. 2000;23(1):138–9.CrossRefPubMed
71.
B Shapiro RR. Disorders of skeletal muscle membrane excitability: myotonia congenita, paramyotonia congenita, periodic paralysis, and related disorders. In: Katirji B KH, Preston D, Ruff R, Shapiro B, editor. Neuromuscular Disorders in Clinical Practice: Butterworth-Heinemann; 2002. p. 987–1020.
72.
Skov M, de Paoli FV, Nielsen OB, Pedersen TH. The anti-convulsants lacosamide, lamotrigine, and rufinamide reduce myotonia in isolated human and rat skeletal muscle. Muscle Nerve. 2017;56(1):136–42.CrossRefPubMed
73.
Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain. 2017;140(9):2295–305.CrossRefPubMed
74.
Leyburn P, Walton JN. The treatment of myotonia: a controlled clinical trial. Brain. 1959;82(1):81–91.CrossRefPubMed
75.
Griggs RC, Davis RJ, Anderson DC, Dove JT. Cardiac conduction in myotonic dystrophy. Am J Med. 1975;59(1):37–42.CrossRefPubMed
76.
Streib EW. AAEE minimonograph #27: differential diagnosis of myotonic syndromes. Muscle Nerve. 1987;10(7):603–15.CrossRefPubMed
77.
Kwiecinski H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand. 1992;86(4):371–5.CrossRefPubMed
78.
79.
Miller TM, Dias da Silva MR, Miller HA, Kwiecinski H, Mendell JR, Tawil R, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004;63(9):1647–55.CrossRefPubMed
80.
Venance SL, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. 2006;129(Pt 1):8–17.CrossRefPubMed
81.
Dalakas MC, Engel WK. Treatment of “permanent” muscle weakness in familial Hypokalemic Periodic Paralysis. Muscle Nerve. 1983;6(3):182–6.CrossRefPubMed
82.
Griggs RC, Engel WK, Resnick JS. Acetazolamide treatment of hypokalemic periodic paralysis. Prevention of attacks and improvement of persistent weakness. Ann Intern Med. 1970;73(1):39–48.CrossRefPubMed
83.
Links TP, Zwarts MJ, Wilmink JT, Molenaar WM, Oosterhuis HJ. Permanent muscle weakness in familial hypokalaemic periodic paralysis. Clinical, radiological and pathological aspects. Brain. 1990;113 ( Pt 6):1873–89.CrossRefPubMed
84.
85.
Jeong HN, Yi JS, Lee YH, Lee JH, Shin HY, Choi YC, et al. Lower-extremity magnetic resonance imaging in patients with hyperkalemic periodic paralysis carrying the SCN4A mutation T704M: 30-month follow-up of seven patients. Neuromuscul Disord. 2018.
86.
Plassart E, Elbaz A, Santos JV, Reboul J, Lapie P, Chauveau D, et al. Genetic heterogeneity in hypokalemic periodic paralysis (hypoPP). Hum Genet. 1994;94(5):551–6.CrossRefPubMed
87.
Horga A, Raja Rayan DL, Matthews E, Sud R, Fialho D, Durran SC, et al. Prevalence study of genetically defined skeletal muscle channelopathies in England. Neurology. 2013;80(16):1472–5.CrossRefPubMedPubMedCentral
88.
Plaster NM, Tawil R, Tristani-Firouzi M, Canun S, Bendahhou S, Tsunoda A, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen’s syndrome. Cell. 2001;105(4):511–9.CrossRefPubMed
89.
Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest. 2002;110(3):381–8.CrossRefPubMedPubMedCentral
90.
Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010;140(1):88–98.CrossRefPubMedPubMedCentral
91.
Chinnery PF, Walls TJ, Hanna MG, Bates D, Fawcett PR. Normokalemic periodic paralysis revisited: does it exist? Ann Neurol. 2002;52(2):251–2.CrossRefPubMed
92.
Tawil R, Ptacek LJ, Pavlakis SG, DeVivo DC, Penn AS, Ozdemir C, et al. Andersen’s syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol. 1994;35(3):326–30.CrossRefPubMed
93.
Sansone V, Griggs RC, Meola G, Ptacek LJ, Barohn R, Iannaccone S, et al. Andersen’s syndrome: a distinct periodic paralysis. Ann Neurol. 1997;42(3):305–12.CrossRefPubMed
94.
Lehmann-Horn F, Jurkat-Rott K, Rudel R. Periodic paralysis: understanding channelopathies. Curr Neurol Neurosci Rep. 2002;2(1):61–9.CrossRefPubMed
95.
96.
Wu F, Mi W, Burns DK, Fu Y, Gray HF, Struyk AF, et al. A sodium channel knockin mutant (NaV1.4-R669H) mouse model of hypokalemic periodic paralysis. J Clin Invest. 2011;121(10):4082–94.CrossRefPubMedPubMedCentral
97.
Wu F, Mi W, Hernandez-Ochoa EO, Burns DK, Fu Y, Gray HF, et al. A calcium channel mutant mouse model of hypokalemic periodic paralysis. J Clin Invest. 2012;122(12):4580–91.CrossRefPubMedPubMedCentral
98.
Matthews E, Hanna MG. Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis? J Physiol. 2010;588(Pt 11):1879–86.CrossRefPubMedPubMedCentral
99.
Tricarico D, Mele A, Conte Camerino D. Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels. Neuromuscul Disord. 2006;16(1):39–45.CrossRefPubMed
100.
Sansone VA. The Dystrophic and Nondystrophic Myotonias. Continuum (Minneap Minn). 2016;22(6, Muscle and Neuromuscular Junction Disorders):1889–915.PubMed
101.
Lichter PR, Newman LP, Wheeler NC, Beall OV. Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol. 1978;85(4):495–502.CrossRefPubMed
102.
Tawil R, Moxley RT, III, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology. 1993;43(6):1105–6.CrossRefPubMed
103.
Griggs RC, Resnick J, Engel WK. Intravenous treatment of hypokalemic periodic paralysis. Arch Neurol. 1983;40(9):539–40.CrossRefPubMed
104.
Stunnenberg BC, Deinum J, Links TP, Wilde AA, Franssen H, Drost G. Cardiac arrhythmias in hypokalemic periodic paralysis: Hypokalemia as only cause? Muscle Nerve. 2014;50(3):327–32.CrossRefPubMed
105.
Matthews E, Portaro S, Ke Q, Sud R, Haworth A, Davis MB, et al. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology. 2011;77(22):1960–4.CrossRefPubMedPubMedCentral
106.
Torres CF, Griggs RC, Moxley RT, Bender AN. Hypokalemic periodic paralysis exacerbated by acetazolamide. Neurology. 1981;31(11):1423–8.CrossRefPubMed
107.
Sternberg D, Maisonobe T, Jurkat-Rott K, Nicole S, Launay E, Chauveau D, et al. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain. 2001;124(Pt 6):1091–9.CrossRefPubMed
108.
Bendahhou S, Cummins TR, Griggs RC, Fu YH, Ptacek LJ. Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. Ann Neurol. 2001;50(3):417–20.CrossRefPubMed
109.
Matthews E, Labrum R, Sweeney MG, Sud R, Haworth A, Chinnery PF, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology. 2009;72(18):1544–7.CrossRefPubMedPubMedCentral
110.
Sansone V, Meola G, Links TP, Panzeri M, Rose MR. Treatment for periodic paralysis. Cochrane Database Syst Rev. 2008(1):CD005045.
111.
Sharp L, Trivedi JR. Treatment and management of neuromuscular channelopathies. Curr Treat Options Neurol. 2014;16(10):313.CrossRefPubMed
112.
Hanna MG, Stewart J, Schapira AH, Wood NW, Morgan-Hughes JA, Murray NM. Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). J Neurol Neurosurg Psychiatry. 1998;65(2):248–50.CrossRefPubMedPubMedCentral
113.
Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, et al. Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol. 2016;7:121.CrossRefPubMedPubMedCentral
Metadaten
Titel
Skeletal Muscle Channelopathies
verfasst von
Lauren Phillips
Jaya R. Trivedi
Publikationsdatum
01.10.2018
Verlag
Springer International Publishing
Erschienen in
Neurotherapeutics / Ausgabe 4/2018
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-018-00678-0

Weitere Artikel der Ausgabe 4/2018

Neurotherapeutics 4/2018 Zur Ausgabe

Review

Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease

Original Article

L-Norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer’s Disease

Review

Diagnosis and Treatment of Mitochondrial Myopathies

Review

Myotonic Dystrophies: Targeting Therapies for Multisystem Disease

Original Article

Inhibition of MyD88 Signaling Skews Microglia/Macrophage Polarization and Attenuates Neuronal Apoptosis in the Hippocampus After Status Epilepticus in Mice

Review

Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise